**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


Washington,
      D.C. 20549


____________________





**FORM
      10-QSB**


**QUARTERLY
      REPORT**





Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934


____________________





For
      the
      Quarter Period Ended


**March
      31, 2006**


**_______________________**





**Nanobac
      Pharmaceuticals, Incorporated**


(Exact
      name of registrant as specified in its charter)




**Florida**
            **0-24696**
            **59-3248917**(State
                or Other Jurisdiction of Incorporation)
            (Commission
                File Number)
            (I.R.S.
                Employer Identification Number)




**4730
      North Habana Avenue, Suite 205, Tampa, Florida 33614**


(Address
      of Principal Executive Office) (Zip Code)





**(813)
      264-2241**


(Registrant’s
      telephone number, including area code)





Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be
      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
      the
      preceding 12 months (or for a shorter period that the registrant was required
      to
      file such reports), and (2) has been subject to such filing requirements for
      the
      past 90 days.





Yes x 
No
o





Indicate
      by check mark whether the Registrant is an accelerated filer (as defined in
      Rule
      12b-2 of the Act):


Yes o 
No
x




The
      number of shares issued and outstanding of the Registrant’s Common Stock, no par
      value, as of May 8, 2006 was
      193,506,760.








1


**NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**








**PART
                I - FINANCIAL INFORMATION****Item
                1: Financial Statements**Condensed
                Consolidated Balance Sheets as of March 31, 2006 (unaudited) and
                December
                31, 2005
            3Condensed
                Consolidated Statements of Operations for the three months ended
                March 31,
                2006 and 2005 (unaudited)
            4Condensed
                Consolidated Statement of Stockholders' Equity for the three months
                ended
                March 31, 2006 (unaudited)
            5Condensed
                Consolidated Statements of Cash Flows for the three months ended
                March 31,
                2006 and 2005 (unaudited)
            6Notes
                to the Condensed Consolidated Financial Statements
            7**Item
                2: Management’s Discussion and Analysis of Financial Condition and Results
                of Operations**
            10**Item
                3: Controls and Procedures**
            19**PART
                II - OTHER INFORMATION****Item
                1: Legal Proceedings**
            19**Item
                2: Unregistered Sales of Equity Securities and Use of
                Proceeds**
            20**Item
                3: Defaults Upon Senior Securities**
            21**Item
                4: Submission of Matters to a Vote of Security
                Holders**
            21**Item
                5: Other Information**
            21**Item
                6: Exhibits**
            21






2




NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES


CONDENSED
      CONSOLIDATED




BALANCE
      SHEETS


(Unaudited)March
                  31, 2006
              
              December
                  31, 2005**ASSETS****CURRENT
                  ASSETS**Cash
              
              $
              626,005
              
              $
              8,975Account
                  receivable
              
              
              12,997
              
              
              3,283Inventory
              
              
              109,191
              
              
              117,280Prepaid
                  expenses
              
              
              40,554
              
              
              43,725Total
                  current assets
              
              
              788,747
              
              
              173,263**FURNITURE
                  AND EQUIPMENT,**less
                  accumulated depreciationof
                  $83,764 at March 31, 2006 and $131,163 atDecember
                  31, 2005
              
              
              74,886
              
              
              106,952**OTHER
                  ASSETS**Security
                  deposits
              
              
              23,521
              
              
              20,695Intangible
                  assets, less accumulated amortizationof
                  $951,351 at March 31, 2006 and $1,539,621 atDecember
                  31, 2005
              
              
              4,291,691
              
              
              5,053,421Goodwill
              
              
              3,615,393
              
              
              3,615,393**Total
                  other assets**
              
              
              7,930,605
              
              
              8,689,509**TOTAL
                  ASSETS**
              
              $
              8,794,238
              
              $
              8,969,724**LIABILITIES
                  AND STOCKHOLDERS' EQUITY****CURRENT
                  LIABILITIES**Accounts
                  payable
              
              $
              272,241
              
              $
              313,932Accrued
                  compensation
              
              
              391,740
              
              
              462,658Accrued
                  expenses
              
              
              487,831
              
              
              376,874Short-term
                  notes payable
              
              
              14,675
              
              
              50,843Other
                  liabilities
              
              
              21,121
              
              
              29,425Related
                  party loans
              
              
              3,676,974
              
              
              2,434,733**Total
                  current liabilities**
              
              
              4,864,582
              
              
              3,668,465**LONG-TERM
                  LIABILITIES**Stock
                  settlement obligation
              
              
              2,836,538
              
              
              2,836,538**Total
                  liabilities**
              
              
              7,701,120
              
              
              6,505,003**COMMITMENTS
                  AND CONTINGENCIES**
              
              
              -
              
              
              -**STOCKHOLDERS'
                  EQUITY**Preferred
                  stock, no par value, 1,000,000 shares authorized,no
                  shares issued and outstanding
              
              
              -
              
              
              -Common
                  stock, no par value, 250,000,000 shares authorized,2006,
                  193,506,760 shares issued and outstanding
              
              
              16,428,5502005,
                  189,006,760 shares issued and outstanding
              
              
              
              
              
              16,307,050Additional
                  paid-in capital
              
              
              3,503,681
              
              
              3,503,681Accumulated
                  deficit
              
              
              (18,868,222
              )
              
              (17,380,535
              )Accumulated
                  other comprehensive income
              
              
              29,109
              
              
              34,525**Total
                  stockholders' equity**
              
              
              1,093,118
              
              
              2,464,721**TOTAL
                  LIABILITIES AND STOCKHOLDERS' EQUITY**
              
              $
              8,794,238
              
              $
              8,969,724




The
      accompanying notes are an integral part of
      these
      financial statements.





3


NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES





CONDENSED
      CONSOLIDATED


STATEMENTS
      OF OPERATIONS





(UNAUDITED)




Three
                  Months
              
              Three
                  Monthsended
              
              endedMarch
                  31, 2006
              
              March
                  31, 2005(Restated)**REVENUE**(Note
                  3)
              
              $
              161,286
              
              $
              151,865**COST
                  OF REVENUE**
              
              
              45,195
              
              
              43,838**GROSS
                  PROFIT**
              
              
              116,091
              
              
              108,027**OPERATING
                  EXPENSES**Selling,
                  general and administrative
              
              
              425,870
              
              
              341,023Research
                  and development
              
              
              354,322
              
              
              346,057Impairment
                  loss on intangible asset
              
              
              585,000
              
              
              -Depreciation
                  and amortization
              
              
              188,217
              
              
              188,252**Total
                  Operating Expenses**
              
              
              1,553,409
              
              
              875,332**OPERATING
                  LOSS**
              
              
              (1,437,318
              )
              
              (767,305
              )**OTHER
                  INCOME (EXPENSES)**Interest
                  expense
              
              
              (38,239
              )
              
              (5,193
              )Loss
                  on stock settlement obligation
              
              
              -
              
              
              (717,908
              )Other,
                  net
              
              
              (12,130
              )
              
              (15,515
              )**LOSS
                  FROM CONTINUING OPERATIONS****BEFORE
                  INCOME TAXES**
              
              
              (1,487,687
              )
              
              (1,505,921
              )**PROVISION
                  FOR INCOME TAXES**
              
              
              -
              
              
              -**NET
                  LOSS**
              
              $
              (1,487,687
              )
              $
              (1,505,921
              )**LOSS
                  PER COMMON SHARE**Basic
                  and Diluted
              
              $
              (0.01
              )
              $
              (0.01
              )**WEIGHTED
                  AVERAGE NUMBER OF****COMMON
                  SHARES OUTSTANDING**Basic
                  and Diluted
              
              
              191,232,034
              
              
              188,394,671


The
      accompanying notes are an integral part of
      these
      financial statements.





4


NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES





CONDENSED
      CONSOLIDATED


STATEMENT
      OF CHANGES IN STOCKHOLDERS' EQUITY


FOR
      THE
      THREE MONTHS ENDED MARCH 31, 2006


(UNAUDITED)





**Accumulated****Additional**
              
              
              
              **Other**
              
              **Other****Common****Stock**
              
              **Paid-in**
              
              **Accumulated**
              
              **Comprehensive**
              
              **Comprehensive****Shares**
              
              **Value**
              
              **Capital**
              
              **Deficit**
              
              **Loss**
              
              **Income**
              
              **Total****Balance,
                  December 31, 2005**
              
              
              **189,006,760**
              
              **$**
              **16,307,050**
              
              **$**
              **3,503,681**
              
              
              **($17,380,535**
              **)**
              
              
              
              **$**
              **34,525**
              
              **$**
              **2,464,721**Stock
                  issued for services
              
              
              4,500,000
              
              
              121,500
              
              
              -
              
              
              -
              
              
              -
              
              
              -
              
              
              121,500Comprehensive
                  loss:Net
                  loss
              
              
              -
              
              
              -
              
              
              -
              
              
              (1,487,687
              )
              
              ($1,487,687
              )
              
              
              
              
              (1,487,687
              )Foreign
                  currency translationadjustment
              
              
              -
              
              
              -
              
              
              -
              
              
              -
              
              
              (5,416
              )
              
              (5,416
              )
              
              (5,416
              )Comprehensive
                  loss
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              ($1,493,103
              )**Balance,
                  March 31, 2006**
              
              
              **193,506,760**
              
              **$**
              **16,428,550**
              
              **$**
              **3,503,681**
              
              **$**
              **(18,868,222**
              **)**
              
              
              
              **$**
              **29,109**
              
              **$**
              **1,093,118**





The
      accompanying notes are an integral part of
      these
      financial statements.




5


NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES





CONDENSED
      CONSOLIDATED


STATEMENTS
      OF CASH FLOWS


(UNAUDITED)





Three
                  Months
              
              Three
                  Monthsended
              
              endedMarch
                  31, 2006
              
              March
                  31, 2005**CASH
                  FLOWS FROM OPERATING ACTIVITIES**
              
              
              
              (Restated)Net
                  loss
              
              $
              (1,487,687
              )
              $
              (1,505,921
              )Adjustments
                  to reconcile net loss to cashflows
                  from operating activities:Depreciation
                  and amortization
              
              
              188,217
              
              
              188,252Impairment
                  loss on intangible assets
              
              
              585,000
              
              
              -Loss
                  on disposition of fixed assets
              
              
              18,330
              
              
              -Loss
                  on stock settlement obligation
              
              
              -
              
              
              717,908Charges
                  for common stock issued for services
              
              
              -
              
              
              10,500Interest
                  expense accrued for stockholder loan
              
              
              38,023
              
              
              3,895Net
                  (increase) decrease in assets:Accounts
                  receivable
              
              
              (9,714
              )
              
              (13,334
              )Inventory
              
              
              8,089
              
              
              (3,860
              )Other
                  assets
              
              
              3,171
              
              
              (5,158
              )Net
                  increase (decrease) in liabilities:Accounts
                  payable
              
              
              (41,691
              )
              
              (16,172
              )Accrued
                  compensation
              
              
              50,582
              
              
              21,458Accrued
                  expenses
              
              
              110,957
              
              
              (18,818
              )Deferred
                  revenue
              
              
              (8,304
              )
              
              1,762Total
                  adjustments
              
              
              942,660
              
              
              886,433**Net
                  cash flows from operating activities**
              
              
              (545,027
              )
              
              (619,488
              )**CASH
                  FLOWS FROM INVESTING ACTIVITIES**Acquisition
                  of furniture and equipment
              
              
              (3,825
              )
              
              (33,868
              )Proceeds
                  from sale of furniture and equipment
              
              
              6,547
              
              
              -Payment
                  of security deposits
              
              
              (2,731
              )
              
              -**Net
                  cash flows from investing activities**
              
              
              (9
              )
              
              (33,868
              )**CASH
                  FLOWS FROM FINANCING ACTIVITIES**Proceeds
                  from issuance of common stockpursuant
                  to subscription agreements
              
              
              -
              
              
              200,000Stock
                  issuance costs
              
              
              -
              
              
              (25,000
              )Proceeds
                  from stockholder loans, net
              
              
              1,204,218
              
              
              448,883Proceeds
                  from notes payable
              
              
              2,601
              
              
              30,907Payment
                  of notes payable
              
              
              (39,000
              )
              
              (16,079
              )**Net
                  cash flows from financing activities**
              
              
              1,167,819
              
              
              638,711**Effect
                  of exchange rate changes**
              
              
              (5,753
              )
              
              10,316Net
                  change in cash
              
              
              617,030
              
              
              (4,329
              )Cash
                  balance, beginning of year
              
              
              8,975
              
              
              17,908**Cash
                  balance, end of period**
              
              $
              626,005
              
              $
              13,579**Supplemental
                  disclosures of cash flow information:**Cash
                  paid for interest
              
              $
              216
              
              $
              1,298**Supplemental
                  schedule of non-cash investing and financing
                  activities:**Common
                  stock issued in exchange for current liabilities
              
              $
              121,500
              
              $
              -




The
      accompanying notes are an integral part of
      these
      financial statements.





6


**NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**


**NOTES
      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**THREE
      MONTHS ENDED MARCH 31, 2006**


**(UNAUDITED)**





**1** . **Nature
      of operations and summary of significant accounting
      polices**





**Nature
      of business**





Nanobac
      Pharmaceuticals, Incorporated and subsidiaries, ("Nanobac”, the "Company", or
      "NNBP") trades under the symbol "NNBP."





NNBP’s
      primary business is research and development of therapeutic and diagnostic
      technologies related to nanobacterium sanguineum (“Nanobacteria”). Nanobacteria
      are believed to be small, calcifying nano-particles that can be found in human
      blood, kidney stones and arterial wall plaques.





**Principles
      of Consolidation**





The
      consolidated financial statements include the accounts of the Company and its
      wholly-owned subsidiaries, Nanobac Sciences LLC, Nanobac OY and Nanobac Research
      Institute LLC. All intercompany transactions and balances have been eliminated
      in consolidation.





**Basis
      of Presentation**





In
      the
      opinion of management, the accompanying financial statements include all
      adjustments, consisting only of normal recurring items, necessary for their
      fair
      presentation in conformity with accounting principles generally accepted in
      the
      United States of America. The results of operations for the three months ended
      March 31, 2006 are not necessarily indicative of the results for a full
      year.





The
      financial statements for the period ended March 31, 2006 and notes thereto
      should be read in conjunction with the financial statements and notes thereto
      for the year ended December 31, 2005 for the Company as filed in the annual
      report on Form 10-KSB, which information is included herein by
      reference.





**Liquidity
      and Management Plans**





The
      accompanying financial statements have been prepared assuming that the Company
      will continue as a going concern. The Company has incurred recurring losses
      and
      has a working capital deficiency at March 31, 2006. The Company is dependent
      on
      continued financing from outside investors including additional shareholder
      loans. All of these matters raise substantial doubt about the ability of the
      Company to continue as a going concern. Management believes that the Company
      will need to raise additional capital in order to launch new clinical trials,
      fund research and development for new treatment areas, and general working
      capital requirements. Capital may be raised through further sales of equity
      securities, which may result in dilution of the position of current
      shareholders. At this time, there is no firm commitment to invest in NNBP.





There
      can
      be no assurances that NNBP will be successful in obtaining debt or equity
      financing in order to achieve its financial objectives and continue as a going
      concern. The financial statements do not include any adjustments to the carrying
      amount of assets and the amounts and classifications of liabilities that might
      result from an adverse outcome of this uncertainty.





7


**NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**


**NOTES
      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**THREE
      MONTHS ENDED MARCH 31, 2006**


**(UNAUDITED)**





**1.
      Nature of operations and summary of significant accounting polices
      (continued)**





**Impairment
      of long-lived assets and intangible assets**





In
      accordance with Statement of Financial Accounting Standards No. 142, “Goodwill
      and Other Intangible Assets” (“SFAS No. 142”), and Statement of Financial
      Accounting Standards, No. 144, “Accounting for the Impairment or Disposal of
      Long-Lived Assets” (“SFAS No. 144”), the Company reviews its non-amortizable
      long-lived assets, including intangible assets and goodwill for impairment
      annually, or sooner whenever events or changes in circumstances indicate the
      carrying amounts of such assets may not be recoverable. Other depreciable or
      amortizable assets are reviewed when indications of impairment exist. Upon
      such
      an occurrence, recoverability of these assets is determined as follows. For
      long-lived assets that are held for use, the Company compares the forecasted
      undiscounted net cash flows to the carrying amount. If it is determined that
      the
      long-lived asset will be unable to recover its carrying amount, then it is
      written down to fair value. For long-lived assets held for sale, assets are
      written down to fair value. Fair value is determined based on discounted cash
      flows or appraised values from management’s estimates, depending upon the nature
      or the assets. Impairment of goodwill is tested using a two step method. The
      first step is to compare the fair value of the reporting unit to its book value,
      including goodwill. If the fair value of the unit is less than its book value,
      the Company then determines the implied fair value of goodwill by deducting
      the
      fair value of the reporting unit’s net assets from the fair value of the
      reporting unit. If the book value of goodwill is greater than its implied fair
      value, the Company writes down goodwill to its implied fair value. As described
      in Note 5, during the three months ended March 31, 2005, the Company’s Product
      Rights was deemed fully impaired based on the Company terminating the marketing
      and sales of dietary supplements and therefore the asset is not expected to
      be
      recoverable from the use or eventual disposition of the asset.





**2.
      Related Party Transactions:**





An
      entity
      controlled by the Chief Executive Officer (who is also the largest stockholder
      of NNBP), has loaned NNBP approximately $3.7 million as of March 31, 2006.
      These
      loans bear interest at the rate of 5% per annum and are due on demand. Interest
      expense for the above loans for the three months ended March 31, 2006 was
      approximately $38,000.





In
      March
      2006, the Company assigned certain products to a related entity owned by the
      Company’s primary stockholder for no compensation (Note 3).


8


**NANOBAC
      PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**


**NOTES
      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**THREE
      MONTHS ENDED MARCH 31, 2006**


**(UNAUDITED)**








**3.
      Discontinuance of sale of supplements**





During
      March 2006, the Company’s management established a plan for Nanobac to
      discontinue the sale of dietary supplements and the Company’s focus to be
      exclusively on the science that will ultimately lead to drug discovery and
      the
      development of diagnostic products. Effective March 30, the Company assigned
      these product rights to an entity owned by the primary stockholder for no
      compensation. As a result of the above decision, a charge to earnings of
      $585,000 for the impairment of the product rights intangible asset has been
      recognized in operating expenses in the accompanying March 31, 2006 condensed
      consolidated statement of operations.





**4.
      Abandonment of lease**





During
      March 2006, the Company ceased occupying certain leased office space in Tampa,
      Florida. As a result of the early abandonment of this office lease, a charge
      to
      earnings of approximately $125,000 for the write-off of leasehold improvements
      and the acceleration of lease payments associated with the abandoned lease
      has
      been recognized in operating expenses in the accompanying March 31, 2006
      condensed consolidated statement of operations.








9





**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations**





**Business**




Nanobac
      Pharmaceuticals, Inc. and its subsidiaries (which may be referred to as
“Nanobac”, “the Company”, “NNBP”, “we”, “us” or “our”) is a life science company
      dedicated to the discovery and developments of products and services to improve
      people's health through the detection and treatment of Calcifying Nano-Particles
      (“CNPs”), otherwise known as "nanobacteria". The Company's pioneering research
      is establishing the pathogenic role of nanobacteria in soft tissue
      calcification, particularly in coronary artery heart disease, prostatitis and
      vascular disease.




Nanobac
      manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the
      detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE(TM)
      and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and
      reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners
      to develop and apply methods for avoiding, detecting, and inactivating or
      eliminating CNPs from raw materials. Nanobac's drug discovery and development
      efforts are focused on developing new and existing compounds that effectively
      inhibit, destroy or neutralize CNPs.




We
      believe that calcification is a significant feature in most diseases that are
      leading causes of death, including heart disease. Calcification is shown in
      numerous studies to block circulation, cause inflammation and cell disruption,
      and is a possible sign of cancers. We have decided to have a sharpened focus
      on
      drug therapy based on findings by Nanobac scientists that certain drugs, when
      combined, are effective at halting the calcification process. Some of these
      drug
      combinations have not been tested in animals or humans. However, the Company
      has
      an advantage in that each of these drugs on its own has an FDA-approved record
      of being safe, therefore regulatory hurdles are significantly lower in every
      national jurisdiction.




Our
      plan
      is to focus on the following priorities over the next 12-18 months:




·
            **Therapy
                -**We
                are entering into agreements to test our proprietary drug combinations
                to
                treat stone-forming diseases, with a preliminary focus on prostatitis,
                which affects millions of men and currently is largely untreatable.
                We
                will also conduct tests with other stone forming diseases such as
                gallstones and kidney stones.




·
            **Infection
                -**The
                gold standard for proving that something is infectious is Koch's
                postulates. We intend to validate earlier findings on Koch's postulates
                with calcifying nanoparticles in laboratory animals, including testing
                whether the infection can be prevented or treated with a proprietary
                drug
                combination.




·
            **Characterization
                -**We
                have preliminary photographic and biochemical evidence that calcifying
                nanoparticles self-replicate in non-precipitating conditions, suggesting
                further that they have the ability to be infectious. We have designed
                an
                experiment with NASA to demonstrate this via time-lapse photography,
                using
                new microscopic technology developed in 2005.




·
            **Thrombosis
                -**Thrombosis
                is the cause of death in most hemodialysis patients. We intend to
                validate
                findings that calcifying nanoparticles discovered in human blood
                provoke
                thrombosis and might be preventable.




·
            **Diagnostics**-
                We believe that our proprietary Elisa antibody test uniquely recognizes
                calcifying nanoparticles known as nanobacteria, and plan to further
                validate the functionality of this diagnostic test.




10


**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**




We
      will
      continue optimizing our proprietary diagnostics, with a clear focus on
      developing effective therapies in cooperation with well-established partners
      including NASA, Mayo Clinic, Cleveland Clinic, and numerous other institutions.
      Once these experiments are completed, we will have a compelling and well-rounded
      scientific basis for the Company to move forward.




***Current
      Developments*** -
      Dr.
      Benedict S. Maniscalco, M.D. joined Nanobac as Director of Clinical Research,
      Medical Director and member of the Board of Directors on March 29, 2006. Dr.
      Maniscaclo replaces Jan Egberts who resigned effective March 29, 2006.




During
      March 2006, we decided to terminate the marketing and selling of dietary
      supplements in order for the Company to focus exclusively on the science related
      to CNPs, which we plan to lead to drug discovery and the development of
      diagnostic products for the detection and treatment of Nanobacteria related
      diseases. Furniture and equipment related to the dietary supplements’ business
      were sold at book value to an entity controlled by our Chief executive Officer
      and largest shareholder.




***Patents
      -*** We
      have
      filed applications for a number of patents, have been granted patents, and
      await
      prosecution of pending application in the US and International
      Stages.





Patent
            
            General
                Subject Matter
            Expiration
                DateUS
                5,135,851
            U.S.
            -Method
                for the culture and detection of nanobacteria also known as calcifying
                nanoparticles
              (issued
                in 1992)
            May
                8, 2010US
                6,706,290
              PCT/EP1999/004555
            U.S.
                & International Application
              (PCT)
            -Methods
                for the eradication of Nanobacteria from articles and animals using
                various novel combinations of systems, chemicals, compounds, drugs,
                prodrugs, supplements, etc.
              (issued
                in 2004)
            Jul
                6, 2018U.S.
                & PCT Applications Filed
            -Methods
                and Compositions (combinations) for treating diseases characterized
                by
                pathological calcification
              (Filed
                in 2004)U.S.
                & PCT Applications Filed
            -Methods
                and combinations of compositions including Bisphosphonates, chelators,
                and
                citrates
              (Filed
                in 2004)U.S.
            -Methods
                for the treatment of disease associated with calcification and/or
                plaque
                formation
              (Filed
                in 2004)U.S.
                & PCT Application Filed
            -Detection
                of antibodies against compositions of conformationally changed proteins
                comprising calcium binding protein hydroxy apatite complexes and
                novel in
                vitro test methods
              (Filed
                in 2005)U.S.
                & PCT Applications filed
            -Methods
                and compositions to detect calcifying nanoparticles including the
                identification and quantification of proteins thereon and correlation
                to
                diseases thereof
              (Filed
                in 2005)





11


**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**





***Patents
      (continued) -*** There
      can
      be no assurance that our patents or pending applications will afford legal
      protection against competitors or provide significant proprietary protection
      or
      competitive advantage. In addition, our patents or pending applications could
      be
      held invalid or unenforceable by a court, or infringed or circumvented by
      others, or others could obtain patents that we would need to license or
      circumvent. Competitors or potential competitors may have filed patent
      applications or received patents, and may obtain additional patents and
      proprietary rights relating to proteins, small molecules, compounds, or
      processes competitive with ours. Additionally, for certain of our product
      candidates, competitors, or potential competitors may claim that their existing
      or pending patents prevent us from commercializing such product candidates
      in
      certain territories. Further, when our patents expire, other companies could
      develop new competitive products to our products.





Trade
      secret protection for our unpatented confidential and proprietary information
      is
      important to us. To protect our trade secrets, we generally require our staff
      members, material consultants, scientific advisors, and parties to collaboration
      and licensing agreements to execute confidentiality agreements upon the
      commencement of employment, the consulting relationship, or the collaboration
      or
      licensing arrangement with us. However, others could either develop
      independently the same or similar information or obtain access to our
      information.





***Change
      of Name -*** During
      April 2004, we announced a name change from Nanobac Pharmaceuticals,
      Incorporated to Nanobac Life Sciences, Inc. to become effective upon approval
      by
      the shareholders. No shareholder meeting was held to approve, therefore the
      name
      was not officially changed in the Florida records.




**Results
      of Operations**




The
      following table presents the percentage of period-over-period dollar change
      for
      the line items in our Condensed Consolidated Statements of Operations for the
      three month periods ended March 31, 2006 and 2005. These comparisons of
      financial results are not necessarily indicative of future results.


**Three
                months ended March**2006
            2005
            %
                ChangeRevenue
            
            $161,286
            $151,865
            6%Cost
                of revenue
            
            45,195
            43,838
            3%Gross
                Profit
            
            116,091
            108,027
            7%Gross
                Profit percentage
            
            72%
            71%Selling,
                general and administrative
            
            425,870
            341,023
            25%Research
                and development
            
            354,322
            346,057
            2%Impairment
                loss on intangible asset
            
            585,000
            -Depreciation
                and amortization
            
            188,217
            188,252
            311%Operating
                loss
            
            (1,437,318)
            (767,305)
            87%Other
                income (Expense)
            
            (50,369)
            (738,616)
            -93%Net
                loss
            
            ($1,487,687)
            ($1,505,921)
            -1%




12




**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**





**Revenue**





Revenue
      for the three months ended March 31, 2006 and 2005 is summarized as
      follows:





**Three
                months ended March**2006
            2005Nanobac
                Supplement
            
            $120,293
            $125,128Observation
                Rights
            
            6,000
            0Diagnostic
                Products
            
            34,993
            26,737$161,286
            $151,865





During
      March 2006, we discontinued the sale of our dietary supplements. Accordingly,
      we
      expect no significant revenue from this revenue source in future periods.





Revenue
      from observation rights is being recognized over the agreement’s 12-month term
      using the straight-line method.





**Cost
      of revenue**





Cost
      of
      revenue consists of direct materials, testing services (for diagnostic products)
      and shipping. As a percentage of revenue, cost of revenue was 28% for the three
      months ended March 31, 2006 compared to approximately 29% for the three months
      ended March 31, 2005.





**Selling,
      General and Administrative**





Approximately
      two-thirds of selling, general and administrative (“SG&A”) expenses are
      comprised of payroll and professional fees. The majority of professional fees
      are related to public company expenses for audit, legal and investor relations.
      Other significant SG&A expenses include facility rental and insurance.





SG&A
      increased to $426,000 for the three months ended March 31, 2006 from $341,000
      for the three months ended March 31, 2005. This increase is attributable to
      the
      abandoned lease described below offset by other net decreases in SG&A.





During
      March 2006, the Company ceased occupying certain leased office space in Tampa,
      Florida. As a result of the early abandonment of this office lease, a charge
      to
      earnings of approximately $106,000 for the acceleration of lease payments
      associated with the abandoned lease has been recognized in the accompanying
      condensed consolidated financial statements for the three months ended March
      31,
      2006.





13


**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**





**Research
      and Development**





For
      the
      three months ended March 31, 2006 and 2005 research and development (“R&D)
      expenses consisted of the following types of expenses:




Three
                Months ended Mar 312006
            2005U.S.
                Payroll and medical directors
            52%
            72%Finland
                payroll and laboratory
            31%
            23%Research
                studies
            10%
            2%Other
            7%
            3%100%
            100%





For
      the
      three months ended March 31, 2006, R&D expenses increased to $354,000 or by
      2% compared to $346,000 for the three months ended March 31, 2005. With our
      renewed focus on R&D, we anticipate increasing R&D expenses during the
      next several months.





**Impairment
      loss on intangible assets**





During
      March 2006, the Company’s management established a plan for Nanobac to
      discontinue the sale of dietary supplements. As a result of the above decision,
      the product rights intangible asset was deemed to be fully impaired and an
      impairment loss on intangible assets of $585,000 has been recognized during
      the
      three months ended March 31, 2006.





**Depreciation
      and amortization**





Depreciation
      and amortization expense amounted to $188,000 for both the three months ended
      March 31, 2006 and 2005. Future amortization expense is expected to decrease
      as
      a result of the impairment loss on the product rights intangible asset recorded
      during the three months ended March 31, 2006.





**Operating
      Loss**





Our
      operating loss remained consistent at $1.5 million for both the three months
      ended March 31, 2006 and 2005. The 2006 loss includes a $106,000 charge for
      the abandonment of our Tampa lease and the $585,000 impairment loss on
      intangible assets.


14


**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**





**Other
      income (expense)**





Other
      income (expense) for the three months ended March 31, 2006 and 2005 is
      summarized as follows:





**Three
                months ended March**2006
            2005Interest
                expenseStockholder
                loan
            
            ($38,023)
            ($3,895)Other
            
            (216)
            (1,298)Loss
                on stock settlement obligation
            
            -
            (717,908)Loss
                on disposition of assets
            
            (18,330)
            -Foreign
                exchange gain (loss)
            
            7,002
            (10,717)Other,
                net
            
            (802)
            (4,798)Total
            
            ($50,369)
            ($738,616)





The
      shares issued in connection with the 2005 and 2004 Subscription Agreement
      transactions are financial instruments with characteristics of both liabilities
      and equity and as such have been presented in the accompanying condensed
      consolidated balance sheets as a liability. Changes in the liability are
      recorded as charges to the March 31, 2005 condensed consolidated statement
      of
      operations as a loss on the stock settlement obligation.





Loss
      on
      disposition of assets is attributable to the abandonment of our lease.





Foreign
      currency gain results from exchange rate changes between the U.S. dollar and
      the
      Euro on intercompany advances between our U.S. subsidiary and our Finland
      subsidiary.








**Net
      Loss**





We
      are
      experiencing significant losses as we conduct research and development related
      to nanobacteria. We believe it will take significant time before we will earn
      meaningful revenue to offset our expenses and there is no assurance that we
      will
      be able to accomplish this goal. As a result of the losses, we are dependent
      on
      affiliates of our CEO and other investors to provide sufficient cash sources
      to
      fund our operations.





15


**Item
      2: Management's Discussion and Analysis of Financial Condition and Results
      of
      Operations (continued)**





**Liquidity
      and Capital Resources**





Since
      the
      United States Bankruptcy Court confirmed a plan of reorganization that allowed
      the Company to emerge from Chapter 11 during calendar 2002, the Company has
      financed its activities primarily through loans made by entities affiliated
      with
      our current Chief Executive Officer (referred to herein as “the Affiliated
      Entities”). These loans were made as funding was needed and were extremely
      advantageous to the Company in that the amounts were funded as the Company
      needed financial infusions and allowed the Company to avoid the costs and
      distractions of attempting to raise these amounts from unrelated parties. It
      is
      unrealistic to believe that unrelated parties would have offered terms as
      generous as those obtained from the Affiliated Entities, and it is also unlikely
      that any financing could have been obtained under any terms without the
      financing of the Affiliated Entities. From time to time the Affiliated Entities
      have agreed to allow a portion of the loan balances to be converted into shares
      of the Company’s common stock. There is no obligation on the part of the
      Affiliated Entities to make additional loans to the Company. The Affiliated
      Entities are also under no obligation to convert any portion of the loan
      balances owed to it into additional shares of the Company’s stock.





Since
      August of 2004, the Company has received $1.4 million (net of $125,000 of
      expenses) from three unaffiliated investors and one affiliate for shares of
      the
      Company’s stock and an equal amount of warrants to acquire additional shares of
      the Company’s stock. The exact number of shares to be issued is dependent upon
      the average closing bid price of the Company’s stock on the five trading days
      immediately prior to the date on which a registration statement for these shares
      is declared effective. The purchase price of the shares is equal to the lesser
      of (1) $.12 or (2) 52% of the average closing price described above. An
      additional $1.5 million is to be received from these investors within five
      days
      of registering the common shares and warrants. A registration statement has
      not
      yet been declared effective for these shares. Successful registration of the
      shares contemplated under the agreements discussed above will provide
      significant amounts of needed capital into the Company. However, there are
      no
      assurances that the SEC will declare a registration statement
      effective.





As
      of
      March 31, 2006, we had total assets of $8.7 million of which only $789,000
      were
      current assets. At March 31, 2006, we had total current liabilities of $4.9
      million and a working capital deficit of $4.1 million. $3.6 million of the
      $4.1
      million working capital deficit is attributable to the related party loans
      from
      Affiliated Entities described above.





Net
      cash
      used in operations for the three months ended March 31, 2006 was $545,000.
      The
      negative cash flow from operations reflects the $1.5 million net loss for the
      period offset by non-cash charges of $585,000 due to impairment loss on
      intangible assets and $188,217 for depreciation and amortization and $106,000
      for the abandonment of a lease (included in accrued expenses).





Net
      cash
      used by investing activities for the three months ended March 31, 2006 included
      $3,000 for the purchase of fixed assets, $3,000 for a security deposit offset
      by
      $6,000 of proceeds from the sale of property and equipment to affiliated
      entities at book value.





Net
      cash
      provided by financing activities for the three months ended March 31, 2006
      was
      $1.2 million, which is attributable to stockholder loans.





As
      noted
      above, cash from stockholder loans financed our net loss and reduction of
      current liabilities. We are dependent on raising additional funding necessary
      to
      implement our business plan. Should we not be successful in raising cash from
      our CEO and other investors, we are unlikely to continue as a going concern.


16


**Item
      2. Management’s Discussion and Analysis of Financial Condition and Results of
      Operations (continued)**




**Critical
      accounting policies**





***Use
      of estimates -*** The
      preparation of financial statements in conformity with accounting principles
      generally accepted in the United States of America requires management to make
      estimates and assumptions that affect the reported amounts of assets and
      liabilities and disclosures of contingent assets and liabilities at the date
      of
      the financial statements and the reported amounts of revenues and expenses
      during the reporting period. Actual results could differ from those
      estimates.





**Forward
      Looking Statements**





Our
      disclosure and analysis in this Form 10-QSB contains some forward-looking
      statements, within the meaning of the Private Securities Litigation Reform
      Act
      of 1995 (“the Act”), that set forth anticipated results based on our plans and
      assumptions. From time to time, we also provide forward-looking statements
      in
      other materials we release to the public as well as oral forward-looking
      statements. Such statements give our current expectations or forecasts of future
      events; they do not relate strictly to historical and current facts. We have
      tried wherever possible to identify such statements by using words such as
      “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”,
“will” and similar expressions in connection with any discussion of future
      operating or financial performance.





In
      light
      of the important factors that can materially affect results, including those
      set
      forth above and elsewhere in this report, the inclusion of forward-looking
      information herein should not be regarded as a representation by us or any
      other
      person that our objectives or plans will be achieved. We may encounter
      competitive, technological, financial and business challenges making it more
      difficult than expected to continue to market our products and services;
      competitive conditions within our industry may change adversely; we may be
      unable to retain existing key management and research personnel; our forecasts
      may not accurately anticipate market demand; and there may be other material
      adverse changes in our operations or business. Certain important factors
      affecting the forward looking statements made herein include, but are not
      limited to (i) accurately forecasting capital expenditures; (ii) obtaining
      new
      sources of external financing; (iii) serving as the nexus for nanobacteria
      research and (iv) conducting successful clinical trials supporting Dr.
      Kajander’s theories that the human body does not recognize nanobacteria as
      harmful, and accordingly, nanobacteria could be the cause of pathological
      disease causing calcification found in multiple diseases. Assumptions relating
      to budgeting, marketing, product development and other management decisions
      are
      subjective in many respects and thus susceptible to interpretations and periodic
      revisions based on actual experience and business developments, the impact
      of
      which may cause the Company to alter its capital expenditure or other budgets,
      which may in turn affect the Company's financial position and results of
      operations.





17


**Item
      2. Management’s Discussion and Analysis of Financial Condition and Results of
      Operations (continued)**




**Quantitative
      and Qualitative Disclosures About Market Risk**





While
      most of our operations are conducted in the United States, we also operate
      a
      laboratory in Kuopio Finland. We face two risks related to foreign currency
      exchange: translation risk and transaction risk. Amounts invested in our Finland
      operations are translated into US Dollars at the exchange rates in effect at
      the
      balance sheet date. Since the functional currency of our Finland subsidiary
      is
      the local currency, foreign currency translation of the balance sheet is
      reflected as a component of stockholders’ equity and does not impact operating
      results.





Our
      Finland subsidiary collects revenue and pays expenses in Euros, mitigating
      transaction risk. Revenues and expenses in Euros translate into varying amounts
      of US Dollars depending upon whether the US Dollar weakens or strengthens
      against the Euro. Therefore, changes in exchange rates may negatively affect
      the
      Company’s consolidated revenues and expenses (as expressed in US Dollars) from
      foreign operations.





Currency
      transaction gains or losses are incurred on our US Subsidiary’s intercompany
      advance to our Finland Subsidiary. We recognize a gain on the intercompany
      advance as the US Dollar weakens against the Euro and we recognize a loss when
      the US Dollar strengthens against the Euro.





The
      Company has not entered into a material amount of foreign currency forward
      exchange contracts or other derivative financial instruments to hedge the
      effects of adverse fluctuations in foreign currency exchange rates.





**Item
      3: Controls and Procedures**





***Disclosure
      controls and procedures***





Under
      the
      supervision and with the participation of our management, including our Chief
      Executive Officer, we have evaluated the effectiveness of the design and
      operation of our disclosure controls and procedures within 90 days of the filing
      date of this report, and, based on this evaluation, our Chief Executive Officer
      has concluded that these controls and procedures are effective.





Disclosure
      controls and procedures are our controls and other procedures that are designed
      to ensure that information required to be disclosed by us in the reports we
      file
      or submit under the Exchange Act is recorded, processed, summarized and
      reported, within the time periods specified in the Securities and Exchange
      Commission's rules and forms. Disclosure controls and procedures include,
      without limitation, controls and procedures designed to ensure that information
      required to be disclosed by us in the reports that we file under the Exchange
      Act is accumulated and communicated to our management, including our principal
      executive officer and principal financial officer, as appropriate to allow
      timely decisions regarding required disclosure.





18


**Item
      3: Controls and Procedures (continued)**





***Section
      404 of the Sarbanes-Oxley Act of 2002***




Section
      404 of the Sarbanes-Oxley Act of 2002 requires our report on Form 10-KSB for
      2006 to include a report of management on internal control over financial
      reporting. Internal control over financial reporting, as defined under these
      rules, is a process designed to provide reasonable assurance regarding the
      reliability of financial reporting and the preparation of financial statements
      for external purposes in accordance with generally accepted accounting
      principles.




In
      our
      report, we will be required, among other things, to assess the effectiveness
      of
      our internal control over financial reporting. The report must also disclose
      any
      material weaknesses in internal control over financial reporting identified
      by
      management, and if there are any material weaknesses, we must conclude that
      our
      internal control over financial reporting was not effective. A material
      weakness, under the applicable rules, is a control deficiency, or combination of
      control deficiencies, that results in more than a remote likelihood that a
      material misstatement of the annual or interim financial statements will not
      be
      prevented or detected.




In
      conducting our ongoing assessment of its internal control over financial
      reporting to prepare for compliance with the requirements under Section 404
      of the Sarbanes-Oxley Act, we have identified a lack of segregation of duties
      to
      be a potential material weakness in internal controls. Lack of segregation
      of
      duties is inherent to our company due to the small number of employees. Our
      assessment is still in process to determine if this situation is actually a
      material weakness or if there are any other material weaknesses.





***Changes
      in internal controls***





There
      were no significant changes in our internal controls or in other factors that
      could significantly affect these controls subsequent to the date of their
      evaluation.





**PART
      II - OTHER INFORMATION**





**Item
      1: Legal Proceedings**





Except
      as
      described below, we know of no material, active or pending legal proceedings
      against us, nor are we involved as a plaintiff in any material proceedings
      or
      pending litigation. There are no proceedings in which any of our directors,
      officers or affiliates, or any registered or beneficial stockholders are an
      adverse party or has a material interest adverse to us.




On
      August
      10, 2004, we were served with a civil action as filed in the Superior Court
      of
      Fulton County State of Georgia by Foltz Martin LLC and Openbook Learning Club,
      Inc. (“Foltz”). This suit alleges that the Company is liable for approximately
      $67,000 of liabilities plus approximately $11,000 interest for services
      performed by the plaintiffs for HealthCentrics, Inc. in 2003 and 2004. The
      Company owned 100% of HealthCentrics from December 2003 through March 2004
      when
      HealthCentrics was sold by the Company to an affiliate. A judgment has been
      entered in the Superior Court of Fulton County, State of Georgia, in favor
      of
      Foltz in this matter. We do not believe that the Company is liable for the
      obligations of HealthCentrics and is currently starting the appeal process.





On
      January 19, 2006, we were served with a civil action as filed in the Superior
      Court of Fulton County State of Georgia by EliteCorp Atlanta, LLC (“EliteCorp”).
      This suit alleges that the Company is liable for approximately $318,000 of
      liabilities plus approximately $110,000 interest for services performed by
      the
      plaintiffs for HealthCentrics, Inc. in 2003 and 2004. We responded to this
      action on February 17, 2006 and denied virtually all the allegations of
      EliteCorp. We do not believe that the Company is liable for the obligations
      of
      HealthCentrics.





19


**Item
      2: Unregistered Sales of Equity Securities and Use of
      Proceeds**





From
      August 2004 through February 2005, we executed Subscription Agreements with
      three unaffiliated investors and one affiliated investor. These investors paid
      us 50% of the subscription price at execution and the remaining 50% is due
      within five days from the date that a registration statement is declared
      effective for the common shares that are being issued. In exchange for the
      cash
      consideration, we are to issue these investors shares of our common stock equal
      to the amount paid divided by the lesser of (a) $0.12 or (b) fifty-two percent
      of the average closing bid price for our common stock for the five days
      immediately prior to the date on which a registration statement is declared
      effective (“The Fixed Price”). In addition, each of these investors will receive
      an equivalent number of warrants with expiration dates of five years from the
      date of issuance. One half of these warrants will be priced at 110% of the
      Fixed
      Price and the remainder will be priced at 150% of the Fixed Price. The minimum
      number of shares and warrants that will be issued under these Subscription
      Agreements (assuming a Fixed Price of $0.12 per share) is as
      follows:


Numberof
                Shares
            Per
                Share
            ProceedsCommon
                Stock:Unaffiliated
                Investors
            
            16,250,000
            $0.12
            $1,950,000Affiliates
            
            8,333,333
            $0.12
            $1,000,00024,583,333
            
            $2,950,000





Number
            Exerciseof
                Warrants
            PriceWarrants:Unaffiliated
                Investors
            
            8,125,000
            $0.13Unaffiliated
                Investors
            
            8,125,000
            $0.18Affiliates
            
            4,166,667
            $0.13Affiliates
            
            4,166,666
            $0.1824,583,333





As
      of
      December 31, 2005, proceeds of $1,475,000 have been received and 12,297,667
      unregistered shares had been issued under the above Subscription Agreements.
      The
      actual number of shares and warrants that ultimately will be issued under these
      Subscription Agreements may be substantially higher due to the variability
      of
      the Fixed Price. Based on our recent traded price of $0.04 to $0.09 per share,
      three to six times as many shares and warrants would be issued as described
      above. Further, if the Fixed Price is less than $0.09 per share, we do not
      have
      sufficient authorized shares to issue the common stock and warrants required
      under the above subscription agreements. Our stockholders need to approve any
      increase in our authorized shares.





Each
      of
      these investors received their shares in reliance upon Section 4(2) of the
      Securities Act of 1933, because each of the holders was knowledgeable,
      sophisticated and had access to comprehensive information about us. At all
      relevant times we were a reporting company under the Securities Exchange Act
      of
      1934 and there was readily available adequate current public information with
      respect to the Company.





A
      success
      fee was awarded to a broker for one of the above unaffiliated investor
      transactions in the form of 5-year warrants equal to 20% of the value of the
      transaction. These warrants have exercise prices equal to $0.16 to $0.22 per
      share for transactions completed to date. Future warrants issued under this
      agreement will have an exercise price equal to NNBP’s stock price on the date of
      closing. We estimate that 2 million warrants will be issued to this broker.





20


**Item
      3: Defaults upon Senior Securities**





None.





**Item
      4: Submission of Matters to a Vote of Security Holders**





None.





**Item
      5: Other Information**





None





**Item
      6: Exhibits and Reports on Form 8-K**





(a)
      The
      following exhibits are filed as part of this report:





Exhibit
      10.27 - Agreement with Calgenex Corporation





Exhibit
      31.1 - Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief
      Executive Officer





Exhibit
      31.2 - Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief
      Financial Officer





Exhibit
      32.1 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to
      Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Executive
      Officer





Exhibit
      32.2 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to
      Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Financial
      Officer




(b)
            Reports
                on Form 8-K





On
      March
      30, 2006, we filed Form 8-KSB to announce the addition of Dr. Benedict
      Maniscalco to our Board of Directors and the resignation of Dr. Jan Egberts
      from
      our Board of Directors.





21


**SIGNATURES**




Pursuant
      to the requirements of the Securities Exchange Act of 1934, the Registrant
      has
      caused this report to be signed on its behalf by the undersigned thereunto
      duly
      authorized.




Dated:
              May 8, 2006
            NANOBAC
              PHARMACEUTICALS, INCORPORATED/s/
              John
              D StantonJohn
              D StantonChief
              Executive Officer


22


**Nanobac
      Pharmaceuticals, Incorporated**








**EXHIBIT
      INDEX**





EXHIBITNUMBER
              DESCRIPTION
              PAGE10.27
              Agreement
                  with Calgenex Corporation
              2431.1
              Certification
                  to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Executive
                  Officer
              2531.2
              Certification
                  to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Financial
                  Officer
              2632.1
              Certification
                  pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
                  906 of
                  the Sarbanes-Oxley Act of 2002 - Chief Executive Officer
              2732.2
              Certification
                  pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
                  906 of
                  the Sarbanes-Oxley Act of 2002 - Chief Financial Officer
              28




23